However, this does not seem significantly higher compared to the other biological agents (55), and, indeed, not only IL-6 inhibition seems associated with a cardiovascular protective effect, but it is currently a therapeutic option in GCA and Takayasu arteritis (56). This evidence concerns the gene IL6 and temporal arteritis.